Desglymidodrine
| Clinical data | |
|---|---|
| Other names | Deglymidodrine; ST-1059; 3,6-Dimethoxy-β-hydroxy-2-phenylethylamine |
| Drug class | α1-Adrenergic receptor agonist; Antihypotensive agent; Vasopressor |
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.322.299 |
| Chemical and physical data | |
| Formula | C10H15NO3 |
| Molar mass | 197.234 g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
Desglymidodrine (developmental code name ST-1059) is the active metabolite of the prodrug antihypotensive agent midodrine.[1][2][3] It acts as a selective α1-adrenergic receptor agonist.[1][2][3] Desglymidodrine is formed from midodrine via deglycination.[1][2][3]
- ^ a b c McClellan KJ, Wiseman LR, Wilde MI (January 1998). "Midodrine. A review of its therapeutic use in the management of orthostatic hypotension". Drugs & Aging. 12 (1): 76–86. doi:10.2165/00002512-199812010-00007. PMID 9467688.
- ^ a b c Cruz DN (May 2000). "Midodrine: a selective alpha-adrenergic agonist for orthostatic hypotension and dialysis hypotension". Expert Opinion on Pharmacotherapy. 1 (4): 835–840. doi:10.1517/14656566.1.4.835. PMID 11249519.
- ^ a b c Gutman LB, Wilson BJ (August 2017). "The Role of Midodrine for Hypotension Outside of the Intensive Care Unit". Journal of Population Therapeutics and Clinical Pharmacology = Journal de la Therapeutique des Populations et de la Pharmacologie Clinique. 24 (3): e45 – e50. doi:10.22374/1710-6222.24.3.4 (inactive 11 July 2025). PMID 28873293.
{{cite journal}}: CS1 maint: DOI inactive as of July 2025 (link)